GlassScriptPhysician profile
Olen Bradley Burns
NPI 1083816813
$7,195.69
in general payments reported to CMS, 2019-2025
36 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $654 · 2021: $992 · 2022: $1,078 · 2023: $1,236 · 2024: $1,492 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,708.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,140.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $861.18 | 2020-2025 | |
| Lilly USA, LLC | $647.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $587.29 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $532.12 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $508.82 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $457.73 | 2022-2025 | Rexulti |
| Amgen INC. | $431.68 | 2019-2025 | Otezla, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $292.74 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.68 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Astellas Pharma US INC | $257.53 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $215.72 | 2020-2025 | Belsomra, Lagevrio, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $124.16 | 2021-2025 | |
| Esperion Therapeutics, INC. | $123.25 | 2020-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $85.69 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olen Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.